New treatments of osteoporosis;Nouveaux traitements de l'ostéoporose

Revue de Medecine Interne

Volumn 25, Issue SUPPL. 5, 2004, Pages

  Chapurlat, R ^a   Delmas, P D ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Bisphophonates; Osteoporosis; SERM; Strontium Ranelate

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CYTOKINE RECEPTOR ANTAGONIST; IBANDRONIC ACID; LASOFOXIFENE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ARTICLE; DRUG EFFICACY; FRAGILITY FRACTURE; HUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; RISK FACTOR; VERTEBRA FRACTURE;

EID: 14844331083     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(04)80057-2     Document Type: Article

References (47)

1. Writing group for the Women's Health Initiative investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
2. The Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy JAMA 291 2004 1701 1712
3. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., and Nevitt M.C. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1996 1535 1541
4. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., and Musliner T.A. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures JAMA 280 1998 2077 2082
5. Harris S.T., Watts N., Genant H.K., McKeever C.D., Hangartner T., and Keller M. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis JAMA 282 1999 1344 1352
6. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., and Brandi M.L. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis Osteoporos Int 11 2000 83 91
7. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., and Roux C. Effect of risedronate on the risk of hip fracture in elderly women N Engl J Med 344 2001 333 340
8. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., and Genant H.K. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene JAMA 282 1999 637 645
9. Riis B.J., Ise J., Von Stein T., Bagger Y., and Christiansen C. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis J Bone Miner Res 16 2001 1871 1878
10. Chestnut C.H. 3rd, Skag A., Christiansen C., Recker R., Stakkestad J.A., and Hoiseth A. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 2004 1241 1249
11. Tanko L.B., Felsenberg D., Czerwinski E., Burdeska A., Jonkanski I., and Hughes C. Oral weekly ibandronate prevents bone loss in postmenopausal women J Int Med 254 2003 159 167
12. Tanko L.B., Mouritzen U., Lehmann H.G., Warming L., Moelgaard A., and Christgau S. Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosedtreatment regimens Bone 32 2003 687 693
13. Cooper C., Emkey R.D., McDonald R.H., Hawker G., Bianchi G., and Wilson K. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis J Clin Endocrinol Metab 88 2003 4609 4615
14. Thiebaud D., Burkhardt P., Kriegbaum H., Huss H., Mulder H., and Juttmann J.R. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis Am J Med 103 1997 298 307
15. Stakkestad J.A., Benevolenskaya L.I., Stepan J.J., Skag A., Nordby A., and Oefjord E. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women Ann Rheum Dis 62 2003 969 975
16. Recker R., Stakkestad J.A., Chestnut C.H. III, Christiansen C., Skag A., and Hoiseth A. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in pstmenopausal osteoporosis Bone 34 2004 890 899
17. Pataki A., Muller K., Green J.R., Ma Y.F., Li Q.N., and Jee W.S. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone before, during and after treatment Anat Rec 249 1997 458 468
18. Berenson J.R., Vescio R., Henick K., Nishikubo C., Rettig M., and Swift R.A. A phase I, open-label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bonedisease Cancer 91 2001 144 154
19. Berenson J.R., Vescio R., Rosen L.S., VonTeichert J.M., Woo M., and Swift R. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of metastatic osteolytic bone disease Clinical Cancer Res 7 2001 478 485
20. Berenson J.R., Rosen L.S., Howell A., Porter L., Coleman R.E., and Morley W. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind randomised, dose-response study Cancer 91 2001 1191 1200
21. th Ar no Meeting of American Society of Clinical Oncology LA9 2000 May 20-23 209a
22. Binkley N., Kimmel D., Bruner J., Haffa A., Davidowitz B., and Meng C. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys J Bone Miner Res 13 1998 1775 1782
23. Reid I.R., Brown J.P., Burkhardt P., Horowitz Z., Richardson P., and Trechsel U. Intravenous zoledronic acid in postmenopausal women with low bone mineral density N Engl J Med 346 2002 653 661
24. Boivin G., Deloffre P., Perrat B., Panczer G., Boudeulle M., and Mauras Y. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S12911) administration J Bone Miner Res 9 1996 1302 1311
25. Marie P.J., Amman P., Boivin G., and Rey C. Mechanisms of action and therapeutic potential of strontium in bone Calcif Tissue Int 69 2001 121 129
26. Marie P.J., Hott M., Modrowski D., De Pollak C., Guillemain J., and Deloffre P. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats J Bone Miner Res 8 1993 607 615
27. Hott M., Deloffre P., Tsouderos Y., and Marie P.J. S12911-2 reduces bone loss induced by short term immobilization in rats Bone 33 2003 115 123
28. Delannoy P., Bazot D., and Marie P.J. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effects in mice Metabolism 51 2002 906 911
29. Short E., and Carter A.C. The usefulness of strontium as an adjuvant to calcium in the remineralization of the skeleton in man Bull Hosp Joint Dis 13 1952 59 66
30. Canalis E., Hott M., Deloffre P., Tsouderos Y., and Marie P.J. The divalent salt 512911 enhances bone cell replication and bone formation in vitro Bone 18 1996 517 523
31. Brown E.M. Is the calcium receptor a molecular target for the actions of strontium on bone? Osteoporos Int 14 Suppl 3 2002 S25 S34
32. Meunier P.J., Slosman D.O., Delmas P.D., Sebert J.L., Brandi M.L., and Albanese C. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a two-year randomized placebo controlled trial J Clin Endocinol Metab 87 2000 2060 2066
33. Reginster J.Y., Deroisy R., Dougdos M., Jupsin I., Colette J., and Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlledPREVOS trial Osteoporos Int 13 2002 925 931
34. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., and Spector T.D. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 2004 459 468
35. Turner C.H., Burr D.B., Hock J.M., Brommage R., and Sato M. The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys Adv Exp Med Biol. 496 2001 165 179
36. Kinkelstein J.S., Klibanski A., Arnold A.L., Toth T.L., Hornstein M.D., and Neer R.M. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone- (1-34): a randomized controlled trial JAMA 280 1998 1067 1073
37. Lindsay R., Nieves J., Formica C., Henneman E., Woelfert L., and Shen V. Randomised controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis Lancet 350 1997 550 555
38. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., and Reginster J.Y. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 2001 1434 1441
39. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., and Lang T.F. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N Engl J Med 349 2003 1207 1215
40. Marcus R., Wang O., Satterwhite J., and Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures inpostmenopausal women with osteoporosis J Bone Miner Res 18 2003 18 23
41. Ettinger B., San Martin J., Crans G., and Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate J Bone Miner Res 19 2004 745 751
42. Kharode Y.P., Green P.D., and Marzolf J.T. Comparison of the effects of bazedoxifene, raloxifene, lasofoxifene and risedronate to hPTH-induced reversal of established osteopenia inovariectomized rats J Bone Miner Res 18 Suppl 2 2003 S273
43. Bolognese M.A., Weiss S.R., and Ettinger M.P. Lasofoxifene: a next generation selective estrogen receptor modulator (SERM) for the prevention of bone loss in postmenopausal women Osteoporos Int 15 Suppl 1 2004 S11
44. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., and Luthy R. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319
45. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., and Burgess T. Osteoprotegerin ligand is a cytokine that regulates osteoclastic differentiation and activation Cell 93 1998 3597 3602
46. Bekker P.J., Holloway D., Nakanishi A., Arrighi M., Leese P.T., and Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women J Bone Miner Res 16 2001 348 360
47. Bekker P.J., Holloway D.L., Rasmussen A.S., Murphy R., Martin S.W., and Leese P.T. A single-class placebo-controlled study of AMG 162, a fully human monoclone antibody to RANKL, in post menopausal women J Bone Miner Res 19 2004 1059 1066